Meisoindigo Acts as a Molecular Glue to Target PKMYT1 for Degradation in Chronic Myeloid Leukemia Therapy
Advanced Science · 2025
DOI: 10.1002/advs.202413676 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Zhao-Xin Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and P…. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Serine-Threonine Kinases, Membrane Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Meisoindigo (Mei) has been clinically utilized for the treatment of chronic myeloid leukemia (CML), yet the precise molecular targets by which it exerts effects remain unclear. Through activity‐based protein profiling (ABPP), the protein kinase, membrane‐associated tyrosine/threonine 1 (PKMYT1) is identified as a direct target of Mei. Specifically, Mei forms a selective and reversible covalent bond with the Cys301 residue of PKMYT1, triggering its K48‐linked polyubiquitination and accelerating proteasomal degradation, which is mediated by the E3 ligase TRIM25. The study reveals that Mei acts as a molecular glue, enhancing the interaction between PKMYT1 and TRIM25 by approximately 30‐fold, thereby facilitating efficient PKMYT1 degradation. Further investigations reveal the pivotal role of PKMYT1 in cell growth. Knockdown of PKMYT1 in K562 cells induces G2/M phase arrest, enhances early apoptosis, and inhibits cell proliferation. In an orthotopic xenograft model, PKMYT1 knockdown delays leukemia progression and reduces lymph node metastasis, reinforcing its role in CML progression and metastasis. These findings provide a molecular rationale for the clinical efficacy of Mei and highlight PKMYT1 as a promising therapeutic target for CML. Additionally, it offers a valuable scaffold and inspiration for the development of novel molecular glue‐based protein degraders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
ORCID-Profile: Shi-Shan Yu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, Z. X., Li, S. Y., Li, F. F., Shi, Q. Y., Tan, C. Y., Wang, X. J., Li, M., Liu, Y. B., Jin, J., Li, Y., & Yu, S. S. (2025). Meisoindigo Acts as a Molecular Glue to Target PKMYT1 for Degradation in Chronic Myeloid Leukemia Therapy. Advanced Science. https://doi.org/10.1002/advs.202413676
Vancouver
Zhang ZX, Li SY, Li FF, Shi QY, Tan CY, Wang XJ, et al. Meisoindigo Acts as a Molecular Glue to Target PKMYT1 for Degradation in Chronic Myeloid Leukemia Therapy. Advanced Science. 2025. doi:10.1002/advs.202413676
BibTeX
@article{Zhang2025,
author = {Zhang, Zhao-Xin and Li, Shu-Ying and Li, Fang-Fei and Shi, Qin-Yan and Tan, Cheng-Yong and Wang, Xiao-Jing and Li, Mi and Liu, Yun-Bao and Jin, Jing and Li, Yong and Yu, Shi-Shan},
title = {Meisoindigo Acts as a Molecular Glue to Target PKMYT1 for Degradation in Chronic Myeloid Leukemia Therapy},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202413676}
}
EUVIMED